Full Press Release Details
Therapeutics Reports First Quarter 2022 Financial Results
Calif.-(BUSINESS WIRE)-May 13, 2022-AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology
company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended
and Capital Resources
January 31, 2022, AgeX borrowed an additional and final $0.5 million of its available credit under a Secured Convertible Facility Agreement,
dated March 30, 2020 and as amended July 21, 2020 and November 12, 2020, with Juvenescence Limited ("Juvenescence"). AgeX
has now drawn the full amount of the credit available under the 2020 Loan Agreement. The outstanding principal balance of the loans under
the 2020 Loan Agreement will become due and payable on March 30, 2023.
Secured Convertible Promissory Note and Security Agreement
February 14, 2022, AgeX and Juvenescence entered into a Secured Convertible Promissory Note (the "Secured Note") pursuant
to which Juvenescence has agreed to provide to AgeX a $13,160,000 line of credit for a period of 12 months. AgeX drew an initial $8,160,000
of the line of credit and used $7,160,000 to pay the outstanding principal and other amounts due as loan origination fees under its 2019
Loan Facility Agreement, as amended, with Juvenescence. The remaining $5 million of the line of credit may be drawn down from time to
time through the first anniversary date subject to Juvenescence's discretion to approve each loan draw. AgeX may not draw more
than $1 million in any subsequent single draw. The outstanding principal balance of the Secured Note will become due and payable on February
Concern Considerations
required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates
whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due
within one year after the date its financial statements are issued. Based on AgeX's most recent projected cash flows, AgeX believes
that its cash and cash equivalents and available sources of debt and equity capital would not be sufficient to satisfy AgeX's anticipated
operating and other funding requirements for the twelve months following the filing of AgeX's Quarterly Report on Form 10-Q for
the three months ended March 31, 2022. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.
and cash equivalents, and restricted cash totaled $0.5 million as of March 31, 2022. Since April 1, 2022, AgeX has received an additional
$1 million of cash through a loan from Juvenescence.
Quarter 2022 Operating Results
Total Revenues for the first quarter of 2022 were $5,000 as compared with $56,000 in the same period in 2021.
expenses: Operating expenses for the three months ended March 31, 2022 were $2 million, as compared with $2.3 million for the same
and development expenses increased by approximately $0.1 million to $0.4 million during the three months ended March 31, 2022 from $0.3
million during the same period in 2021. The net increase was primarily attributable to $0.1 million in scientific consulting,
outside research and service expenses under a sponsored research agreement with a university.
and administrative expenses for the three months ended March 31, 2022 decreased by $0.3 million to $1.7 million as compared to $2.0 million
during the same period in 2021. The net decrease is primarily attributable to decreases of $0.3 million in professional fees for legal
services and $0.2 million for consulting expenses. These decreases were offset to some extent by a $0.1 million increase in noncash stock-based
compensation expense to consultants and directors and $0.1 million in insurance expense and certain non-recurring general office expenses
income (expense), net: Other expense, net in 2022 consists primarily of $544,000 amortization of deferred debt cost to interest expense,
$20,000 other debt related expenses included in interest expense and $87,000 unrealized loss on change in fair value of warrants issued
to Juvenescence in connection with borrowings under the Secured Note. Other income, net in 2021 consists primarily of $437,000 from
forgiveness of a Paycheck Protection Program loan including accrued interest on February 19, 2021, offset by approximately $267,000
of amortization of deferred debt cost to interest expense.
Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases
to increase healthspan and combat the effects of aging. AgeX's PureStem and UniverCyte manufacturing and
immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent
stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical
cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.
AgeX's revolutionary longevity platform induced Tissue Regeneration (iTR ) aims to unlock cellular immortality and regenerative
capacity to reverse age-related changes within tissues. HyStem is AgeX's delivery technology to stably engraft
PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around
its broad IP estate and proprietary technology platforms and therapy product candidates.
more information, please visit www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook,
statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will,"
"believes," "plans," "anticipates," "expects," "estimates" should also be
considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially
from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties
that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found
in more detail in the "Risk Factors" section of AgeX's most recent Annual Report on Form 10-K and Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events
and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update
or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release,
except as required by applicable law.
THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
thousands, except par value amounts)
| March 31, 2022 | December 31, 2021 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 448 | $ | 584 | ||||
| Accounts and grants receivable, net | - | 25 | ||||||
| Prepaid expenses and other current assets | 1,381 | 1,625 | ||||||
| Total current assets | 1,829 | 2,234 | ||||||
| Deposits | 50 | 50 | ||||||
| Intangible assets, net | 837 | 870 | ||||||
| TOTAL ASSETS | $ | 2,716 | $ | 3,154 | ||||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable and accrued liabilities | $ | 1,097 | $ | 771 | ||||
| Loan due to Juvenescence, net of debt issuance cost, current portion | 6,657 | 7,140 | ||||||
| Related party payables, net | 69 | 70 | ||||||
| Warrant liability | 1,615 | - | ||||||
| Insurance premium liability and other current liabilities | 661 | 986 | ||||||
| Total current liabilities | 10,099 | 8,967 | ||||||
| Loan due to Juvenescence, net of debt issuance cost, net of current portion | 4,208 | 6,062 | ||||||
| TOTAL LIABILITIES | 14,307 | 15,029 | ||||||
| Commitments and contingencies | ||||||||
| STOCKHOLDERS' DEFICIT | ||||||||
| Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of March 31, 2022 and December 31, 2021 | - | - | ||||||
| Common stock, $0.0001 par value, 100,000 shares authorized; and 37,943 and 37,941 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 4 | 4 | ||||||
| Additional paid-in capital | 96,903 | 93,912 | ||||||
| Accumulated deficit | (108,454 | ) | (105,748 | ) | ||||
| AgeX Therapeutics, Inc. stockholders' deficit | (11,547 | ) | (11,832 | ) | ||||
| Noncontrolling interest | (44 | ) | (43 | ) | ||||
| Total stockholders' deficit | (11,591 | ) | (11,875 | ) | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ | 2,716 | $ | 3,154 |
THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
thousands, except per share data)
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| REVENUES: | ||||||||
| Grant revenues | $ | - | $ | 46 | ||||
| Other revenues | 5 | 10 | ||||||
| Total revenues | 5 | 56 | ||||||
| Cost of sales | (1 | ) | (3 | ) | ||||
| Gross profit | 4 | 53 | ||||||
| OPERATING EXPENSES: | ||||||||
| Research and development | 396 | 324 | ||||||
| General and administrative | 1,660 | 2,022 | ||||||
| Total operating expenses | 2,056 | 2,346 | ||||||
| Gain on deconsolidation of LifeMap Sciences | - | 106 | ||||||
| Loss from operations | (2,052 | ) | (2,187 | ) | ||||
| OTHER INCOME (EXPENSE), NET: | ||||||||
| Interest expense, net | (571 | ) | (243 | ) | ||||
| Other income (expense), net | (84 | ) | 437 | |||||
| Total other income (expense), net | (655 | ) | 194 | |||||
| NET LOSS FROM CONTINUING OPERATIONS | (2,707 | ) | (1,993 | ) | ||||
| NET LOSS FROM DISCONTINUED OPERATIONS | - | (103 | ) | |||||
| NET LOSS | (2,707 | ) | (2,096 | ) | ||||
| Net loss attributable to noncontrolling interest from continuing operations | 1 | 1 | ||||||
| Net loss attributable to noncontrolling interest from discontinued operations | - | 7 | ||||||
| NET LOSS ATTRIBUTABLE TO AGEX | $ | (2,706 | ) | $ | (2,088 | ) | ||
| NET LOSS PER COMMON SHARE: | ||||||||
| BASIC AND DILUTED | ||||||||
| Continuing operations | $ | (0.07 | ) | $ | (0.05 | ) | ||
| Discontinued operations | - | (0.01 | ) | |||||
| $ | (0.07 | ) | $ | (0.06 | ) | |||
| WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||||||||
| BASIC AND DILUTED | 37,942 | 37,729 | ||||||
| AMOUNTS ATTRIBUTABLE TO AGEX: | ||||||||
| Loss from continuing operations | $ | (2,706 | ) | $ | (1,992 | ) | ||
| Loss from discontinued operations | - | (96 | ) | |||||
| NET LOSS ATTRIBUTABLE TO AGEX | $ | (2,706 | ) | $ | (2,088 | ) |
THERAPEUTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| (unaudited) | ||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss attributable to AgeX | $ | (2,706 | ) | $ | (1,992 | ) | ||
| Net loss attributable to noncontrolling interest | (1 | ) | (1 | ) | ||||
| Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities: | ||||||||
| Gain on deconsolidation of LifeMap Sciences | - | (106 | ) | |||||
| Gain on extinguishment of debt (Paycheck Protection Program Loan) | - | (437 | ) | |||||
| Unrealized loss on change in fair value of warrants | 87 | - | ||||||
| Amortization of intangible assets | 33 | 33 | ||||||
| Amortization of debt issuance cost | 544 | 267 | ||||||
| Stock-based compensation | 239 | 178 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts and grants receivable, net | 25 | 105 | ||||||
| Prepaid expenses and other current assets | 243 | 117 | ||||||
| Accounts payable and accrued liabilities | 207 | (346 | ) | |||||
| Related party payables | 19 | - | ||||||
| Insurance premium liability | (325 | ) | (304 | ) | ||||
| Other current liabilities | (1 | ) | (54 | ) | ||||
| Net cash used in operating activities from continuing operations | (1,636 | ) | (2,540 | ) | ||||
| Net cash used in operating activities from discontinued operations | - | (90 | ) | |||||
| Net cash used in operating activities | (1,636 | ) | (2,630 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from the sale of LifeMap Sciences | - | 466 | ||||||
| Partial collection on loan due from LifeMap Sciences | - | 250 | ||||||
| Net cash provided by investing activities from continuing operations | - | 716 | ||||||
| Deconsolidation of cash and cash equivalents from discontinued operations | - | (50 | ) | |||||
| Net cash provided by investing activities | - | 666 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Draw down on loan facilities from Juvenescence | 1,500 | 2,000 | ||||||
| Proceeds from the issuance of common stock | - | 496 | ||||||
| Net cash provided by financing activities from continuing operations | 1,500 | 2,496 | ||||||
| Partial payment on loan due to AgeX from discontinued operations | - | (250 | ) | |||||
| Net cash provided by financing activities | 1,500 | 2,246 | ||||||
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | (136 | ) | 282 | |||||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||||
| At beginning of the period | 634 | 577 | ||||||
| At end of the period | $ | 498 | $ | 859 |